Unknown

Dataset Information

0

AMPK activation with glabridin ameliorates adiposity and lipid dysregulation in obesity.


ABSTRACT: In this study, we demonstrate that activation of AMP-activated protein kinase (AMPK) with glabridin alleviates adiposity and hyperlipidemia in obesity. In several obese rodent models, glabridin decreased body weight and adiposity with a concomitant reduction in fat cell size. Further, glabridin ameliorated fatty liver and plasma levels of triglyceride and cholesterol. In accordance with these findings, glabridin suppressed the expression of lipogenic genes such as sterol regulatory element binding transcription factor (SREBP)-1c, fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD)-1 in white adipose tissues and liver, whereas it elevated the expression of fatty acid oxidation genes such as carnitine palmitoyl transferase (CPT)1, acyl-CoA oxidase (ACO), and peroxisome proliferator-activated receptor (PPAR)? in muscle. Moreover, glabridin enhanced phosphorylation of AMPK in muscle and liver and promoted fatty acid oxidation by modulating mitochondrial activity. Together, these data suggest that glabridin is a novel AMPK activator that would exert therapeutic effects in obesity-related metabolic disorders.

SUBMITTER: Lee JW 

PROVIDER: S-EPMC3371239 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

AMPK activation with glabridin ameliorates adiposity and lipid dysregulation in obesity.

Lee Joo-Won JW   Choe Sung Sik SS   Jang Hagoon H   Kim Jiyeong J   Jeong Hyun Woo HW   Jo Hyunsun H   Jeong Kyeong-Hoon KH   Tadi Surendar S   Park Myoung Gyu MG   Kwak Tae Hwan TH   Man Kim Jin J   Hyun Dong-Hoon DH   Kim Jae Bum JB  

Journal of lipid research 20120409 7


In this study, we demonstrate that activation of AMP-activated protein kinase (AMPK) with glabridin alleviates adiposity and hyperlipidemia in obesity. In several obese rodent models, glabridin decreased body weight and adiposity with a concomitant reduction in fat cell size. Further, glabridin ameliorated fatty liver and plasma levels of triglyceride and cholesterol. In accordance with these findings, glabridin suppressed the expression of lipogenic genes such as sterol regulatory element bindi  ...[more]

Similar Datasets

| S-EPMC8468764 | biostudies-literature
| S-EPMC9483033 | biostudies-literature
| S-EPMC6266584 | biostudies-literature
| S-EPMC6801774 | biostudies-literature
| S-EPMC5514886 | biostudies-other
| S-EPMC5501612 | biostudies-literature
| S-EPMC6479292 | biostudies-literature
| S-EPMC7782552 | biostudies-literature
| S-EPMC4848522 | biostudies-other
| S-EPMC4217731 | biostudies-literature